Jim Simons’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Jim Simons’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-39,300	Closed	-$395K	–	4211
2023 Q4	$395K	Sell	39,300 -7,300	-16%	-$33.1K	﹤0.01%	2878
2023 Q3	$134K	Sell	46,600 -2,500	-5%	-$9.14K	﹤0.01%	3186
2023 Q2	$187K	Buy	49,100 +200	+0.4%	+$560	﹤0.01%	3322
2023 Q1	$91K	Sell	48,900 -100	-0.2%	-$209	﹤0.01%	3518
2022 Q4	$113K	Sell	49,000 -1,300	-3%	-$3.98K	﹤0.01%	3575
2022 Q3	$162K	Buy	50,300 +400	+0.8%	+$1.3K	﹤0.01%	3450
2022 Q2	$274K	Buy	49,900 +26,300	+111%	+$81.8K	﹤0.01%	3510
2022 Q1	$55K	Buy	+23,600	New	+$80.4K	﹤0.01%	3899

Jim Simons's GRCL Position: Q1 2024 in Review

Jim Simons sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 39,300 shares — an estimated $395K sold.

Jim Simons first reported a position in GRCL in Q1 2022 and held it in 8 quarters. The position peaked at $395K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Jim Simons reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Jim Simons sold 39,300 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $395K.
Jim Simons first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2022 and held it in 8 quarters.
Jim Simons's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $395K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.